Evidence map›Paper›PMID 38890575›Full record

ArticleBMC infectious diseases2024

Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study.

Huan Zhang, Xiaojiao Tan, Zheng Zhang, Chenxi Wang, Haiqing Shi, Yao Li, Jianbo Li, Yan Kang, Xiaodong Jin, Xuelian Liao

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huan Zhang *Department of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Xiaojiao Tan *Department of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Zheng ZhangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Chenxi WangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Haiqing ShiDepartment of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Yao LiDepartment of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Jianbo LiDepartment of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Yan KangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China.
Xiaodong Jin *Department of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China. zh_jxd@163.com.
Xuelian Liao *Department of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang Street, Chengdu, Sichuan, 610041, China. liaoxuelian@scu.edu.cn.

Funding

Key Research and Development Project of Science and Technology Department of Sichuan Province 2021YFS0003the National key research and development plan in China 2022YFC2009804
6 · The paper itself

Abstract

backgroundThere is an urgent need for therapeutic strategies for inpatients with severe or critical COVID-19. The evaluation of the clinical benefits of nirmatrelvir and ritonavir (Nmr/r) for these patients beyond five days of symptom onset is insufficient.

methodsA new propensity score-matched cohort was constructed by using multicenter data from 6695 adult inpatients with COVID-19 from December 2022 to February 2023 in China after the epidemic control measures were lifted across the country. The severity of disease of the inpatients was based on the tenth trial edition of the Guidelines on the Diagnosis and Treatment of COVID-19 in China. The symptom onset of 1870 enrolled severe or critical inpatients was beyond five days, and they received either Nmr/r plus standard treatment or only standard care. The ratio of patients whose SOFA score improved more than 2 points, crucial respiratory endpoints, changes in inflammatory markers, safety on the seventh day following the initiation of Nmr/r treatment, and length of hospital stay were evaluated.

resultsIn the Nmr/r group, on Day 7, the number of patients with an improvement in SOFA score ≥ 2 was much greater than that in the standard treatment group (P = 0.024) without a significant decrease in glomerular filtration rate (P = 0.815). Additionally, the rate of new intubation was lower (P = 0.004) and the no intubation days were higher (P = 0.003) in the first 7 days in the Nmr/r group. Other clinical benefits were limited.

conclusionsOur study may provide new insight that inpatients with severe or critical COVID-19 beyond five days of symptom onset benefit from Nmr/r. Future studies, particularly randomized controlled trials, are necessary to verify the above findings.

Indexed as

COVID-19 Drug TreatmentPropensity ScoreRitonavirSARS-CoV-2AdultAgedAntiviral AgentsChinaCOVID-19FemaleHumansInpatientsLength of StayMaleMiddle AgedRetrospective StudiesAntiviral AgentsRitonavirCOVID-19CriticalNirmatrelvir and ritonavirSevere

Identifiers

PMID38890575
PMCPMC11184924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.